Noteworthy Thursday Option Activity: DKS, OXY, RVMD

Occidental Petroleum options traded 66,513 contracts today (≈6.7 million underlying shares), about 64.5% of OXY's one‑month average daily volume (10.3M), led by 6,252 contracts in the $40 put expiring Jan. 16, 2026 (≈625,200 shares). Revolution Medicines saw 19,134 option contracts (≈1.9M underlying shares), roughly 64% of its one‑month average daily volume (3.0M), led by 2,818 contracts in the $115 call expiring Jan. 16, 2026 (≈281,800 shares). The concentrated strikes and high notional volumes indicate significant positioning or hedging activity that could affect near‑term intraday flows and volatility in OXY and RVMD.

Analysis

Market structure: Large concentrated long-dated OXY put flow (6,252 contracts at $40 Jan‑16‑2026) signals either institutional hedging of sizeable equity exposure or a bearish view on oil/asset-specific downside; this benefits options sellers, diversified commodity hedgers and volatility providers while pressuring levered E&P equity holders if positions are directional. RVMD concentrated long calls ($115 Jan‑16‑2026, 2,818 contracts) points to takeover/trial-success speculation that benefits biotech acquirers and long volatility players and hurts short-biotech momentum players if a positive catalyst materializes.

Risk assessment: Tail risk for OXY includes a sharp oil price collapse (Brent < $65 within 6–12 months) or credit event that could wipe equity value; for RVMD the tail is binary trial failure/M&A walk which could move shares >30% in days. Near term (days–weeks) positioning risk dominates (gamma/liquidity), medium term (months) depends on oil inventories, earnings and trial readouts, long term to Jan‑2026 reflects structural views on energy transition and drug pipeline viability. Hidden dependency: large trades may be flow from structured products or single-account block trades — not pure directional conviction — so IV skew and subsequent unwind can reverse moves rapidly.

Trade implications: If you believe OXY put demand is hedging (not directional), consider selling structured premium (credit spreads) into elevated IV; if you believe RVMD calls are informed, favor asymmetric long exposure (call debit spreads) sized to event risk. Cross-asset: heavy OXY hedging could pressure high-yield E&P bonds and widen CDS, so hedge equity trades with HY protection if size warrants. Monitor IV rank, open interest concentration, Brent spot and scheduled catalysts (OXY earnings, RVMD trial/partnership windows) over next 30–90 days.

Key Decisions for Investors

• Sell OXY Jan‑16‑2026 $40/$30 put credit spread sized so max portfolio risk = 0.5%; enter only if OXY 30‑day IV > 20% and collect ≥$1.50 credit per contract; unwind/trim if OXY < $35 for 3 consecutive sessions or Brent < $70 for 10 trading days.
• Establish a bullish RVMD position via Jan‑16‑2026 $90/$115 call debit spread allocating 1–2% of portfolio capital; target 50–100% return or exit if RVMD < $75 for two weeks or a negative Phase/partnership announcement occurs. Enter when RVMD IV rank < 50 to avoid overpaying.
• Run a dollar‑neutral pair: long RVMD Jan‑2026 $90/$115 call spread vs short OXY Jan‑2026 $40/$30 put spread with equal max loss, size combined exposure ≤2% portfolio to express biotech upside vs energy hedging; rebalance monthly and close within 30 days of major catalysts.
• Reduce concentrated exposure to levered E&P (e.g., XOP or individual names with debt/EBITDA < 3x) by 20–30% if OXY 30‑day IV rises >40% from current levels or OXY stock falls >15% in 10 trading days, reallocating proceeds to selective defensive energy infrastructure or cash.